MSB Trading - 2020, page-1516

Unfortunately I do not agree with your interpretation:

"The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate’s existing Fast Track designation. If approved, remestemcel-L is planned to be launched in the US in 2020."
The word "will" creates a promise , a contractual obligation . Hence in the context " the final module will be filed during January"-(will) is not merely stating a future event, it is creating a promise to perform.
Hence since they have not filed the final BLA in January which has since gone past they breached their contractual obligation.
What happens after the final filing of the BLA is no longer in the hands of MSB but the FDA and the Fast Track Designation is again the prerogative of the FDA.
Whether or not MSB in the past did not inform the market is irrelevant. They did so on this occasion and they failed.
The point I was making was about credibility and shareholders were expecting the final BLA filing and I for one am disappointed.